Over the past year, Novo Nordisk (NVO) has significantly underperformed both its industry peers and the broader market. While the Health Care Select Sector SPDR ETF recorded gains during the same period, Novo Nordisk’s stock price experienced a deep correction and is currently trading near its lowest level in four years. This performance is primarily attributed to multiple challenges facing the company: sales growth has fallen short of investor expectations, particularly due to a downward revision in the projected growth rate of its star product Wegovy; simultaneously, the company is under pressure from litigation with dispensing pharmacies over the sales of generic GLP-1 drugs, which has dampened market confidence. Furthermore, events such as management changes have collectively contributed to the downward pressure on the stock price. From a valuation perspective, the company’s current price-to-earnings ratio is significantly below its historical average, placing it at a historical low in terms of profitability, which makes its stock appear highly attractive.
Looking ahead to 2026, Novo Nordisk has several positive factors that could potentially drive a recovery in its stock price. First, the company’s legal efforts to protect its core products, such as Ozempic and Wegovy, could directly boost sales revenue if progress is made. Second, the company’s research and development pipeline continues to advance, particularly with an oral weight-loss drug in late-stage clinical trials. If successfully launched, this drug could open up a significant new growth avenue for the company. These potential positive developments stand in stark contrast to the current market sentiment, which has fully priced in pessimism and undervaluation. Any performance improvements or R&D breakthroughs that exceed current low expectations could serve as catalysts for a stock price rebound.
From a broader perspective, the healthcare sector has underperformed the overall market in recent years, suggesting potential opportunities for valuation recovery. As market concerns about certain high-valuation sectors increase, healthcare stocks with reasonable valuations and long-term stable growth attributes are likely to regain investor favor. As a leading global healthcare company, Novo Nordisk’s fundamental business remains solid. Its current low valuation level has largely factored in recent negative developments, providing long-term investors with an attractive risk-reward opportunity. Considering its established market position for existing products, potential relief from legal issues, and the prospects of new product launches, Novo Nordisk possesses the potential to achieve both performance recovery and valuation re-rating in 2026.
